Baker Bros. Advisors secured Board seat in Replimune Group (REPL)
Key Summary: On March 5, 2025, Michael Goller, Baker Bros. Advisors. was appointed to the Board
Market Cap: $886 million | Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer.
On March 5, 2025, the board acting on the recommendation of the Nominating and Corporate Governance Committee, (i) expanded the Board from nine members to ten, and (ii) appointed Michael Goller, Baker Bros. Advisors, to the Board. Source
Member discussion